Search Results - "Xiong, Chengjie"

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease by Bateman, Randall J, Xiong, Chengjie, Benzinger, Tammie L.S, Fagan, Anne M, Goate, Alison, Fox, Nick C, Marcus, Daniel S, Cairns, Nigel J, Xie, Xianyun, Blazey, Tyler M, Holtzman, David M, Santacruz, Anna, Buckles, Virginia, Oliver, Angela, Moulder, Krista, Aisen, Paul S, Ghetti, Bernardino, Klunk, William E, McDade, Eric, Martins, Ralph N, Masters, Colin L, Mayeux, Richard, Ringman, John M, Rossor, Martin N, Schofield, Peter R, Sperling, Reisa A, Salloway, Stephen, Morris, John C

“…In this study of a cohort of adults with genetic mutations that cause autosomal dominant Alzheimer's disease, researchers identified abnormalities in…”
Get full text

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study by Vos, Stephanie JB, MSc, Xiong, Chengjie, Prof, Visser, Pieter Jelle, MD, Jasielec, Mateusz S, MS, Hassenstab, Jason, PhD, Grant, Elizabeth A, PhD, Cairns, Nigel J, Prof, Morris, John C, Prof, Holtzman, David M, Prof, Fagan, Anne M, Prof

“…Summary Background New research criteria for preclinical Alzheimer's disease have been proposed, which include stages for cognitively normal individuals with…”
Get full text

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease by Preische, Oliver, Schultz, Stephanie A., Apel, Anja, Kuhle, Jens, Kaeser, Stephan A., Barro, Christian, Gräber, Susanne, Kuder-Buletta, Elke, LaFougere, Christian, Laske, Christoph, Vöglein, Jonathan, Levin, Johannes, Masters, Colin L., Martins, Ralph, Schofield, Peter R., Rossor, Martin N., Graff-Radford, Neill R., Salloway, Stephen, Ghetti, Bernardino, Ringman, John M., Noble, James M., Chhatwal, Jasmeer, Goate, Alison M., Benzinger, Tammie L. S., Morris, John C., Bateman, Randall J., Wang, Guoqiao, Fagan, Anne M., McDade, Eric M., Gordon, Brian A., Jucker, Mathias

“…Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique…”
Get full text

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease by Morris, John C, Schindler, Suzanne E, McCue, Lena M, Moulder, Krista L, Benzinger, Tammie L S, Cruchaga, Carlos, Fagan, Anne M, Grant, Elizabeth, Gordon, Brian A, Holtzman, David M, Xiong, Chengjie

“…Racial differences in molecular biomarkers for Alzheimer disease may suggest race-dependent biological mechanisms. To ascertain whether there are racial…”
Get more information

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging by Morris, John C., Roe, Catherine M., Xiong, Chengjie, Fagan, Anne M., Goate, Alison M., Holtzman, David M., Mintun, Mark A.

“…Objective To examine interactions of apolipoprotein E (APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively…”
Get full text

Sleep quality and preclinical Alzheimer disease by Ju, Yo-El S, McLeland, Jennifer S, Toedebusch, Cristina D, Xiong, Chengjie, Fagan, Anne M, Duntley, Stephen P, Morris, John C, Holtzman, David M

“…Sleep and circadian problems are very common in Alzheimer disease (AD). Recent animal studies suggest a bidirectional relationship between sleep and β-amyloid…”
Get more information

Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis by Ryman, Davis C, Acosta-Baena, Natalia, Aisen, Paul S, Bird, Thomas, Danek, Adrian, Fox, Nick C, Goate, Alison, Frommelt, Peter, Ghetti, Bernardino, Langbaum, Jessica B.S, Lopera, Francisco, Martins, Ralph, Masters, Colin L, Mayeux, Richard P, McDade, Eric, Moreno, Sonia, Reiman, Eric M, Ringman, John M, Salloway, Steve, Schofield, Peter R, Sperling, Reisa, Tariot, Pierre N, Xiong, Chengjie, Morris, John C, Bateman, Randall J

“…OBJECTIVE:To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based…”
Get full text

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging by Schindler, Suzanne E., Gray, Julia D., Gordon, Brian A., Xiong, Chengjie, Batrla-Utermann, Richard, Quan, Marian, Wahl, Simone, Benzinger, Tammie L.S., Holtzman, David M., Morris, John C., Fagan, Anne M.

“…Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease,…”
Get full text

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease by Sutphen, Courtney L., McCue, Lena, Herries, Elizabeth M., Xiong, Chengjie, Ladenson, Jack H., Holtzman, David M., Fagan, Anne M.

“…Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition…”
Get full text

Dural lymphatics regulate clearance of extracellular tau from the CNS by Patel, Tirth K, Habimana-Griffin, LeMoyne, Gao, Xuefeng, Xu, Baogang, Achilefu, Samuel, Alitalo, Kari, McKee, Celia A, Sheehan, Patrick W, Musiek, Erik S, Xiong, Chengjie, Coble, Dean, Holtzman, David M

“…Alzheimer's disease is characterized by two main neuropathological hallmarks: extracellular plaques of amyloid-β (Aβ) protein and intracellular aggregates of…”
Get full text

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model by Bateman, Randall J, Benzinger, Tammie L, Berry, Scott, Clifford, David B, Duggan, Cynthia, Fagan, Anne M, Fanning, Kathleen, Farlow, Martin R, Hassenstab, Jason, McDade, Eric M, Mills, Susan, Paumier, Katrina, Quintana, Melanie, Salloway, Stephen P, Santacruz, Anna, Schneider, Lon S, Wang, Guoqiao, Xiong, Chengjie

“…Abstract Introduction The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or…”
Get full text

Absence of Practice Effects in Preclinical Alzheimer's Disease by Hassenstab, Jason, Ruvolo, David, Jasielec, Mateusz, Xiong, Chengjie, Grant, Elizabeth, Morris, John C.

“…Objective: To describe how practice effects influence cognitive trajectories and determine if a reduction in practice effects is a potential marker of…”
Get full text

A real-time 3D electromagnetic navigation system for percutaneous pedicle screw fixation in traumatic thoraco-lumbar fractures: implications for efficiency, fluoroscopic time, and accuracy compared with those of conventional fluoroscopic guidance by Yao, Yawei, Jiang, Xiang, Wei, Tanjun, Yao, Zhipeng, Wu, Boyu, Xu, Feng, Xiong, Chengjie

“…Purpose Navigation is becoming more useful in percutaneous pedicle screw fixation (PPSF). The aim of this study was to compare the efficiency, fluoroscopic…”
Get full text

Age and amyloid effects on human central nervous system amyloid-beta kinetics by Patterson, Bruce W., Elbert, Donald L., Mawuenyega, Kwasi G., Kasten, Tom, Ovod, Vitaliy, Ma, Shengmei, Xiong, Chengjie, Chott, Robert, Yarasheski, Kevin, Sigurdson, Wendy, Zhang, Lily, Goate, Alison, Benzinger, Tammie, Morris, John C., Holtzman, David, Bateman, Randall J.

“…Objective Age is the single greatest risk factor for Alzheimer's disease (AD), with the incidence doubling every 5 years after age 65. However, our…”
Get full text

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age by Sutphen, Courtney L, Jasielec, Mateusz S, Shah, Aarti R, Macy, Elizabeth M, Xiong, Chengjie, Vlassenko, Andrei G, Benzinger, Tammie L S, Stoops, Erik E J, Vanderstichele, Hugo M J, Brix, Britta, Darby, Heather D, Vandijck, Manu L J, Ladenson, Jack H, Morris, John C, Holtzman, David M, Fagan, Anne M

“…Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the…”
Get more information

Three-dimensional high-definition exoscope (Kestrel View II) in anterior cervical discectomy and fusion: a valid alternative to operative microscope-assisted surgery by Yao, Yawei, Xiong, Chengjie, Wei, Tanjun, Yao, Zhipeng, Zhu, Fangqiang, Xu, Feng

“…Background Operative microscope (OM) has greatly advanced modern spine surgery, but remains limited by several drawbacks. Therefore, a three-dimensional (3D)…”
Get full text

Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease by Benzinger, Tammie L S, Blazey, Tyler, Jack, Jr, Clifford R, Koeppe, Robert A, Su, Yi, Xiong, Chengjie, Raichle, Marcus E, Snyder, Abraham Z, Ances, Beau M, Bateman, Randall J, Cairns, Nigel J, Fagan, Anne M, Goate, Alison, Marcus, Daniel S, Aisen, Paul S, Christensen, Jon J, Ercole, Lindsay, Hornbeck, Russ C, Farrar, Angela M, Aldea, Patricia, Jasielec, Mateusz S, Owen, Christopher J, Xie, Xianyun, Mayeux, Richard, Brickman, Adam, McDade, Eric, Klunk, William, Mathis, Chester A, Ringman, John, Thompson, Paul M, Ghetti, Bernardino, Saykin, Andrew J, Sperling, Reisa A, Johnson, Keith A, Salloway, Stephen, Correia, Stephen, Schofield, Peter R, Masters, Colin L, Rowe, Christopher, Villemagne, Victor L, Martins, Ralph, Ourselin, Sebastien, Rossor, Martin N, Fox, Nick C, Cash, David M, Weiner, Michael W, Holtzman, David M, Buckles, Virginia D, Moulder, Krista, Morris, John C

“…Major imaging biomarkers of Alzheimer’s disease include amyloid deposition [imaged with [ ¹¹C]Pittsburgh compound B (PiB) PET], altered glucose metabolism…”
Get full text

A family of estimators to diagnostic accuracy when candidate tests are subject to detection limits—Application to diagnosing early stage Alzheimer disease by Xiong, Chengjie, Luo, Jingqin, Agboola, Folasade, Grant, Elizabeth, Morris, John C.

“…In disease diagnosis, individuals are usually assumed to be one of the two basic types, healthy or diseased, as typically based on an established gold…”
Get full text

YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease by Craig-Schapiro, Rebecca, Perrin, Richard J, Roe, Catherine M, Xiong, Chengjie, Carter, Deborah, Cairns, Nigel J, Mintun, Mark A, Peskind, Elaine R, Li, Ge, Galasko, Douglas R, Clark, Christopher M, Quinn, Joseph F, D'Angelo, Gina, Malone, James P, Townsend, R. Reid, Morris, John C, Fagan, Anne M, Holtzman, David M

“…Background Disease-modifying therapies for Alzheimer's disease (AD) would be most effective during the preclinical stage (pathology present, cognition intact)…”
Get full text

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease by Fagan, Anne M, Xiong, Chengjie, Jasielec, Mateusz S, Bateman, Randall J, Goate, Alison M, Benzinger, Tammie L S, Ghetti, Bernardino, Martins, Ralph N, Masters, Colin L, Mayeux, Richard, Ringman, John M, Rossor, Martin N, Salloway, Stephen, Schofield, Peter R, Sperling, Reisa A, Marcus, Daniel, Cairns, Nigel J, Buckles, Virginia D, Ladenson, Jack H, Morris, John C, Holtzman, David M

“…Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD) begins many years before the appearance of cognitive symptoms. Biomarkers…”
Get more information